|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leufkens AM, van den Bosch MAAJ, van
Leeuwen MS and Siersema PD: Diagnostic accuracy of computed
tomography for colon cancer staging: A systematic review. Scand J
Gastroenterol. 46:887–894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu YJ, Li X, Chen TT, Wang JX, Zhou YX,
Mu XL, Du Y, Wang JL, Tang J and Liu JY: Personalised
neoantigen-based therapy in colorectal cancer. Clin Transl Med.
13:e14612023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barker HE, Paget JTE, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Le DT, Hubbard-Lucey VM, Morse MA, Heery
CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA
Jr, et al: A blueprint to advance colorectal cancer
immunotherapies. Cancer Immunol Res. 5:942–949. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fletcher R, Wang YJ, Schoen RE, Finn OJ,
Yu J and Zhang L: Colorectal cancer prevention: Immune modulation
taking the stage. Biochim Biophys Acta Rev Cancer. 1869:138–148.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milette S, Fiset PO, Walsh LA, Spicer JD
and Quail DF: The innate immune architecture of lung tumors and its
implication in disease progression. J Pathol. 247:589–605. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bronte V, Brandau S, Chen SH, Colombo MP,
Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A,
Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived
suppressor cell nomenclature and characterization standards. Nat
Commun. 7:121502016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Condamine T and Gabrilovich DI: Molecular
mechanisms regulating myeloid-derived suppressor cell
differentiation and function. Trends Immunol. 32:19–25. 2011.
View Article : Google Scholar :
|
|
14
|
Condamine T, Mastio J and Gabrilovich DI:
Transcriptional regulation of myeloid-derived suppressor cells. J
Leukoc Biol. 98:913–922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao F, Hoechst B, Duffy A,
Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF and Korangy F:
S100A9 a new marker for monocytic human myeloid-derived suppressor
cells. Immunology. 136:176–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Veglia F, Sanseviero E and Gabrilovich DI:
Myeloid-derived suppressor cells in the era of increasing myeloid
cell diversity. Nat Rev Immunol. 21:485–498. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Groth C, Hu X, Weber R, Fleming V,
Altevogt P, Utikal J and Umansky V: Immunosuppression mediated by
myeloid-derived suppressor cells (MDSCs) during tumour progression.
Br J Cancer. 120:16–25. 2019. View Article : Google Scholar :
|
|
18
|
Veglia F, Perego M and Gabrilovich D:
Myeloid-derived suppressor cells coming of age. Nat Immunol.
19:108–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marigo I, Bosio E, Solito S, Mesa C,
Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, et
al: Tumor-induced tolerance and immune suppression depend on the
C/EBPbeta transcription factor. Immunity. 32:790–802. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Consonni FM, Porta C, Marino A, Pandolfo
C, Mola S, Bleve A and Sica A: Myeloid-derived suppressor cells:
Ductile targets in disease. Front Immunol. 10:9492019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim HX, Kim TS and Poh CL: Understanding
the differentiation, expansion, recruitment and suppressive
activities of myeloid-derived suppressor cells in cancers. Int J
Mol Sci. 21:35992020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma T, Renz BW, Ilmer M, Koch D, Yang Y,
Werner J and Bazhin AV: Myeloid-derived suppressor cells in solid
tumors. Cells. 11:3102022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Talmadge JE and Gabrilovich DI: History of
myeloid-derived suppressor cells. Nat Rev Cancer. 13:739–752. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gabrilovich DI: Myeloid-derived suppressor
cells. Cancer Immunol Res. 5:3–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fleming V, Hu X, Weber R, Nagibin V, Groth
C, Altevogt P, Utikal J and Umansky V: Targeting myeloid-derived
suppressor cells to bypass tumor-induced immunosuppression. Front
Immunol. 9:3982018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Z, Guo J, Weng L, Tang W, Jin S and
Ma W: Myeloid-derived suppressor cells-new and exciting players in
lung cancer. J Hematol Oncol. 13:102020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui C, Lan P and Fu L: The role of
myeloid-derived suppressor cells in gastrointestinal cancer. Cancer
Commun (Lond). 41:442–471. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hess NJ, Kink JA and Hematti P: Exosomes,
MDSCs and tregs: A new frontier for GVHD prevention and treatment.
Front Immunol. 14:11433812023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang
G, Yin B, Divino CM and Chen SH: Immune stimulatory receptor CD40
is required for T-cell suppression and T regulatory cell activation
mediated by myeloid-derived suppressor cells in cancer. Cancer Res.
70:99–108. 2010. View Article : Google Scholar :
|
|
30
|
Gaißler A, Bochem J, Spreuer J, Ottmann S,
Martens A, Amaral T, Wagner NB, Claassen M, Meier F, Terheyden P,
et al: Early decrease of blood myeloid-derived suppressor cells
during checkpoint inhibition is a favorable biomarker in metastatic
melanoma. J Immunother Cancer. 11:e0068022023. View Article : Google Scholar
|
|
31
|
Kaplan RN, Riba RD, Zacharoulis S, Bramley
AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et
al: VEGFR1-positive haematopoietic bone marrow progenitors initiate
the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Condamine T, Ramachandran I, Youn JI and
Gabrilovich DI: Regulation of tumor metastasis by myeloid-derived
suppressor cells. Annu Rev Med. 66:97–110. 2015. View Article : Google Scholar :
|
|
33
|
Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y,
Shu P, Li D and Wang Y: Myeloid-derived suppressor cells as
immunosuppressive regulators and therapeutic targets in cancer.
Signal Transduct Target Ther. 6:3622021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fědorová L, Pilátová K, Selingerová I,
Bencsiková B, Budinská E, Zwinsová B, Brychtová V, Langrová M, Šefr
R, Valík D and Zdražilová Dubská L: Circulating myeloid-derived
suppressor cell subsets in patients with colorectal
cancer-exploratory analysis of their biomarker potential. Klin
Onkol. 31(Suppl 2): S88–S92. 2018. View Article : Google Scholar
|
|
35
|
Zhang Y, Xu J, Zhang N, Chen M, Wang H and
Zhu D: Targeting the tumour immune microenvironment for cancer
therapy in human gastrointestinal malignancies. Cancer Lett.
458:123–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gabrilovich DI, Bronte V, Chen SH, Colombo
MP, Ochoa A, Ostrand-Rosenberg S and Schreiber H: The terminology
issue for myeloid-derived suppressor cells. Cancer Res. 67:425–426.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Youn JI, Nagaraj S, Collazo M and
Gabrilovich DI: Subsets of myeloid-derived suppressor cells in
tumor-bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ueha S, Shand FHW and Matsushima K:
Myeloid cell population dynamics in healthy and tumor-bearing mice.
Int Immunopharmacol. 11:783–788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mandruzzato S, Brandau S, Britten CM,
Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van
der Burg SH, Welters MJ and Walter S: Toward harmonized phenotyping
of human myeloid-derived suppressor cells by flow cytometry:
Results from an interim study. Cancer Immunol Immunother.
65:161–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Z, Yuan R, Hu S, Yuan W and Sun Z:
Roles of the exosomes derived from myeloid-derived suppressor cells
in tumor immunity and cancer progression. Front Immunol.
13:8179422022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cassetta L, Bruderek K,
Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM, Lin A,
Santegoets K, Horzum U, Godinho-Santos A, et al: Differential
expansion of circulating human MDSC subsets in patients with
cancer, infection and inflammation. J Immunother Cancer.
8:e0012232020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Flores-Toro JA, Luo D, Gopinath A,
Sarkisian MR, Campbell JJ, Charo IF, Singh R, Schall TJ, Datta M,
Jain RK, et al: CCR2 inhibition reduces tumor myeloid cells and
unmasks a checkpoint inhibitor effect to slow progression of
resistant murine gliomas. Proc Natl Acad Sci USA. 117:1129–1138.
2020. View Article : Google Scholar :
|
|
43
|
Takacs GP, Kreiger CJ, Luo D, Tian G,
Garcia JS, Deleyrolle LP, Mitchell DA and Harrison JK:
Glioma-derived CCL2 and CCL7 mediate migration of immune
suppressive CCR2+/CX3CR1+ M-MDSCs into the
tumor microenvironment in a redundant manner. Front Immunol.
13:9934442023. View Article : Google Scholar
|
|
44
|
Singh L, Muise ES, Bhattacharya A, Grein
J, Javaid S, Stivers P, Zhang J, Qu Y, Joyce-Shaikh B, Loboda A, et
al: ILT3 (LILRB4) promotes the immunosuppressive function of
tumor-educated human monocytic myeloid-derived suppressor cells.
Mol Cancer Res. 19:702–716. 2021. View Article : Google Scholar
|
|
45
|
Veglia F, Hashimoto A, Dweep H, Sanseviero
E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G,
et al: Analysis of classical neutrophils and polymorphonuclear
myeloid-derived suppressor cells in cancer patients and
tumor-bearing mice. J Exp Med. 218:e202018032021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Condamine T, Dominguez GA, Youn JI,
Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A,
Nefedova Y, Lin C, et al: Lectin-type oxidized LDL receptor-1
distinguishes population of human polymorphonuclear myeloid-derived
suppressor cells in cancer patients. Sci Immunol. 1:aaf89432016.
View Article : Google Scholar
|
|
47
|
Joshi S and Sharabi A: Targeting
myeloid-derived suppressor cells to enhance natural killer
cell-based immunotherapy. Pharmacol Ther. 235:1081142022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tian X, Shen H, Li Z, Wang T and Wang S:
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor
microenvironment. J Hematol Oncol. 12:842019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dumitru CA, Moses K, Trellakis S, Lang S
and Brandau S: Neutrophils and granulocytic myeloid-derived
suppressor cells: Immunophenotyping, cell biology and clinical
relevance in human oncology. Cancer Immunol Immunother.
61:1155–1167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gunaydin G, Kesikli SA and Guc D: Cancer
associated fibroblasts have phenotypic and functional
characteristics similar to the fibrocytes that represent a novel
MDSC subset. Oncoimmunology. 4:e10349182015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mazza EM, Zoso A, Mandruzzato S, Bronte V,
Serafini P, Inverardi L and Bicciato S: Gene expression profiling
of human fibrocytic myeloid-derived suppressor cells (f-MDSCs).
Genom Data. 2:389–392. 2014. View Article : Google Scholar
|
|
52
|
Bizymi N, Georgopoulou A, Mastrogamvraki
N, Matheakakis A, Gontika I, Fragiadaki I, Mavroudi I and Papadaki
HA: Myeloid-derived suppressor cells (MDSC) in the umbilical cord
blood: Biological significance and possible therapeutic
applications. J Clin Med. 11:7272022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Haile LA, Gamrekelashvili J, Manns MP,
Korangy F and Greten TF: CD49d is a new marker for distinct
myeloid-derived suppressor cell subpopulations in mice. J Immunol.
185:203–210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Alshetaiwi H, Pervolarakis N, McIntyre LL,
Ma D, Nguyen Q, Rath JA, Nee K, Hernandez G, Evans K, Torosian L,
et al: Defining the emergence of myeloid-derived suppressor cells
in breast cancer using single-cell transcriptomics. Sci Immunol.
5:eaay60172020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dienstmann R, Connor K and Byrne AT;
COLOSSUS Consortium: Precision therapy in RAS mutant colorectal
cancer. Gastroenterology. 158:806–811. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Vakiani E, Janakiraman M, Shen R, Sinha R,
Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al:
Comparative genomic analysis of primary versus metastatic
colorectal carcinomas. J Clin Oncol. 30:2956–2962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liao W, Overman MJ, Boutin AT, Shang X,
Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, et al: KRAS-IRF2 axis
drives immune suppression and immune therapy resistance in
colorectal cancer. Cancer Cell. 35:559–572.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian
Y, Li W, Chen H, Gou H, Liu D, et al: In colorectal cancer cells
with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA
demethylation to increase WNT signaling, stemness, and drug
resistance. Gastroenterology. 159:2163–2180.e6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou Q, Peng Y, Ji F, Chen H, Kang W, Chan
LS, Gou H, Lin Y, Huang P, Chen D, et al: Targeting of SLC25A22
boosts the immunotherapeutic response in KRAS-mutant colorectal
cancer. Nat Commun. 14:46772023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Johnson B: Targeting myeloid-derived
suppressor cell trafficking as a novel immunotherapeutic approach
in microsatellite stable colorectal cancer. Cancers (Basel).
15:54842023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bao Y, Zhai J, Chen H, Wong CC, Liang C,
Ding Y, Huang D, Gou H, Chen D, Pan Y, et al: Targeting
m6A reader YTHDF1 augments antitumour immunity and
boosts anti-PD-1 efficacy in colorectal cancer. Gut. 72:1497–1509.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li Y, He X, Lu X, Gong Z, Li Q, Zhang L,
Yang R, Wu C, Huang J, Ding J, et al: METTL3 acetylation impedes
cancer metastasis via fine-tuning its nuclear and cytosolic
functions. Nat Commun. 13:63502022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen H, Pan Y, Zhou Q, Liang C, Wong CC,
Zhou Y, Huang D, Liu W, Zhai J, Gou H, et al: METTL3 inhibits
antitumor immunity by targeting m6A-BHLHE41-CXCL1/CXCR2
axis to promote colorectal cancer. Gastroenterology. 163:891–907.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhai J, Chen H, Wong CC, Peng Y, Gou H,
Zhang J, Pan Y, Chen D, Lin Y, Wang S, et al: ALKBH5 drives immune
suppression via targeting AXIN2 to promote colorectal cancer and is
a target for boosting immunotherapy. Gastroenterology. 165:445–462.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhao D, Wu L, Hong M, Zheng S, Wu X, Ye H,
Chen F, Zhang D, Liu X, Meng X, et al: DKK-1 and its influences on
bone destruction: A comparative study in collagen-induced arthritis
mice and rheumatoid arthritis patients. Inflammation. 47:129–144.
2024. View Article : Google Scholar
|
|
67
|
Fujimura T, Kambayashi Y and Aiba S:
Crosstalk between regulatory T cells (Tregs) and myeloid derived
suppressor cells (MDSCs) during melanoma growth. Oncoimmunology.
1:1433–1434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li N, Kang Y, Wang L, Huff S, Tang R, Hui
H, Agrawal K, Gonzalez GM, Wang Y, Patel SP and Rana TM: ALKBH5
regulates anti-PD-1 therapy response by modulating lactate and
suppressive immune cell accumulation in tumor microenvironment.
Proc Natl Acad Sci USA. 117:20159–20170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Husain Z, Seth P and Sukhatme VP:
Tumor-derived lactate and myeloid-derived suppressor cells: Linking
metabolism to cancer immunology. Oncoimmunology. 2:e263832013.
View Article : Google Scholar
|
|
70
|
Hayes C, Donohoe CL, Davern M and Donlon
NE: The oncogenic and clinical implications of lactate induced
immunosuppression in the tumour microenvironment. Cancer Lett.
500:75–86. 2021. View Article : Google Scholar
|
|
71
|
Bejarano L, Jordāo MJC and Joyce JA:
Therapeutic targeting of the tumor microenvironment. Cancer Discov.
11:933–959. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hegde S, Leader AM and Merad M: MDSC:
Markers, development, states, and unaddressed complexity. Immunity.
54:875–884. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Walz A, Peveri P, Aschauer H and
Baggiolini M: Purification and amino acid sequencing of NAF, a
novel neutrophil-activating factor produced by monocytes. Biochem
Biophys Res Commun. 149:755–761. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Schulz O, Hammerschmidt SI, Moschovakis GL
and Förster R: Chemokines and chemokine receptors in lymphoid
tissue dynamics. Annu Rev Immunol. 34:203–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li BH, Garstka MA and Li ZF: Chemokines
and their receptors promoting the recruitment of myeloid-derived
suppressor cells into the tumor. Mol Immunol. 117:201–215. 2020.
View Article : Google Scholar
|
|
76
|
McClellan JL, Davis JM, Steiner JL, Enos
RT, Jung SH, Carson JA, Pena MM, Carnevale KA, Berger FG and Murphy
EA: Linking tumor-associated macrophages, inflammation, and
intestinal tumorigenesis: Role of MCP-1. Am J Physiol Gastrointest
Liver Physiol. 303:G1087–1095. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast-tumour metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chang YH, Huang YL, Tsai HC, Chang AC, Ko
CY, Fong YC and Tang CH: Chemokine ligand 2 promotes migration in
osteosarcoma by regulating the miR-3659/MMP-3 axis. Biomedicines.
11:27682023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Behfar S, Hassanshahi G, Nazari A and
Khorramdelazad H: A brief look at the role of monocyte
chemoattractant protein-1 (CCL2) in the pathophysiology of
psoriasis. Cytokine. 110:226–231. 2018. View Article : Google Scholar
|
|
80
|
Chun E, Lavoie S, Michaud M, Gallini CA,
Kim J, Soucy G, Odze R, Glickman JN and Garrett WS: CCL2 promotes
colorectal carcinogenesis by enhancing polymorphonuclear
myeloid-derived suppressor cell population and function. Cell Rep.
12:244–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Molon B, Ugel S, Del Pozzo F, Soldani C,
Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, et
al: Chemokine nitration prevents intratumoral infiltration of
antigen-specific T cells. J Exp Med. 208:1949–1962. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Katoh H, Wang D, Daikoku T, Sun H, Dey SK
and Dubois RN: CXCR2-expressing myeloid-derived suppressor cells
are essential to promote colitis-associated tumorigenesis. Cancer
Cell. 24:631–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wang Y, Ding Y, Deng Y, Zheng Y and Wang
S: Role of myeloid-derived suppressor cells in the promotion and
immunotherapy of colitis-associated cancer. J Immunother Cancer.
8:e0006092020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Grauers Wiktorin H, Nilsson MS, Kiffin R,
Sander FE, Lenox B, Rydström A, Hellstrand K and Martner A:
Histamine targets myeloid-derived suppressor cells and improves the
anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer
Immunol Immunother. 68:163–174. 2019. View Article : Google Scholar :
|
|
85
|
Martin RK, Saleem SJ, Folgosa L, Zellner
HB, Damle SR, Nguyen GK, Ryan JJ, Bear HD, Irani AM and Conrad DH:
Mast cell histamine promotes the immunoregulatory activity of
myeloid-derived suppressor cells. J Leukoc Biol. 96:151–159. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Sulsenti R and Jachetti E: Frenemies in
the microenvironment: Harnessing mast cells for cancer
immunotherapy. Pharmaceutics. 15:16922023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Obermajer N, Muthuswamy R, Lesnock J,
Edwards RP and Kalinski P: Positive feedback between PGE2 and COX2
redirects the differentiation of human dendritic cells toward
stable myeloid-derived suppressor cells. Blood. 118:5498–5505.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zelenay S, van der Veen AG, Böttcher JP,
Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais
R, Quezada SA, et al: Cyclooxygenase-dependent tumor growth through
evasion of immunity. Cell. 162:1257–1270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lin Y, He Z, Ye J, Liu Z, She X, Gao X and
Liang R: Progress in understanding the IL-6/STAT3 pathway in
colorectal cancer. Onco Targets Ther. 13:13023–13032. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Su YL, Banerjee S, White SV and
Kortylewski M: STAT3 in tumor-associated myeloid cells:
Multitasking to disrupt immunity. Int J Mol Sci. 19:18032018.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Sinha P, Clements VK, Fulton AM and
Ostrand-Rosenberg S: Prostaglandin E2 promotes tumor progression by
inducing myeloid-derived suppressor cells. Cancer Res.
67:4507–4513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tang C, Sun H, Kadoki M, Han W, Ye X,
Makusheva Y, Deng J, Feng B, Qiu D, Tan Y, et al: Blocking Dectin-1
prevents colorectal tumorigenesis by suppressing prostaglandin E2
production in myeloid-derived suppressor cells and enhancing IL-22
binding protein expression. Nat Commun. 14:14932023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lu W, Yu W, He J, Liu W, Yang J, Lin X,
Zhang Y, Wang X, Jiang W, Luo J, et al: Reprogramming
immunosuppressive myeloid cells facilitates immunotherapy for
colorectal cancer. EMBO Mol Med. 13:e127982021. View Article : Google Scholar :
|
|
94
|
Molfetta R and Paolini R: The
controversial role of intestinal mast cells in colon cancer. Cells.
12:4592023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Cheon EC, Khazaie K, Khan MW, Strouch MJ,
Krantz SB, Phillips J, Blatner NR, Hix LM, Zhang M, Dennis KL, et
al: Mast cell 5-lipoxygenase activity promotes intestinal polyposis
in APCDelta468 mice. Cancer Res. 71:1627–1636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ostrand-Rosenberg S and Fenselau C:
Myeloid-derived suppressor cells: Immune-suppressive cells that
impair antitumor immunity and are sculpted by their environment. J
Immunol. 200:422–431. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Rahma OE and Hodi FS: The Intersection
between tumor angiogenesis and immune suppression. Clin Cancer Res.
25:5449–5457. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Xiang X, Poliakov A, Liu C, Liu Y, Deng
ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, et al: Induction of
myeloid-derived suppressor cells by tumor exosomes. Int J Cancer.
124:2621–2633. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Fenselau C and Ostrand-Rosenberg S:
Molecular cargo in myeloid-derived suppressor cells and their
exosomes. Cell Immunol. 359:1042582021. View Article : Google Scholar :
|
|
100
|
Gu J, Lv X, Li W, Li G, He X, Zhang Y, Shi
L and Zhang X: Deciphering the mechanism of Peptostreptococcus
anaerobius-induced chemoresistance in colorectal cancer: The
important roles of MDSC recruitment and EMT activation. Front
Immunol. 14:12306812023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Abed J, Emgård JEM, Zamir G, Faroja M,
Almogy G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA, et al:
Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma
enrichment by binding to tumor-expressed gal-GalNAc. Cell Host
Microbe. 20:215–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Han J, Zhang B, Zhang Y, Yin T, Cui Y, Liu
J, Yang Y, Song H and Shang D: Gut microbiome: Decision-makers in
the microenvironment of colorectal cancer. Front Cell Infect
Microbiol. 13:12999772023. View Article : Google Scholar :
|
|
103
|
Kostic AD, Chun E, Robertson L, Glickman
JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold
GL, et al: Fusobacterium nucleatum potentiates intestinal
tumorigenesis and modulates the tumor-immune microenvironment. Cell
Host Microbe. 14:207–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hashemi Goradel N, Heidarzadeh S,
Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N and Negahdari
B: Fusobacterium nucleatum and colorectal cancer: A mechanistic
overview. J Cell Physiol. 234:2337–2344. 2019. View Article : Google Scholar
|
|
105
|
Cassetta L, Baekkevold ES, Brandau S,
Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O,
et al: Deciphering myeloid-derived suppressor cells: Isolation and
markers in humans, mice and non-human primates. Cancer Immunol
Immunother. 68:687–697. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wu Y, Yi M, Niu M, Mei Q and Wu K:
Myeloid-derived suppressor cells: An emerging target for anticancer
immunotherapy. Mol Cancer. 21:1842022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Gallina G, Dolcetti L, Serafini P, De
Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I,
Zanovello P, et al: Tumors induce a subset of inflammatory
monocytes with immunosuppressive activity on CD8+ T
cells. J Clin Invest. 116:2777–2790. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Bronte V and Zanovello P: Regulation of
immune responses by L-arginine metabolism. Nat Rev Immunol.
5:641–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Rodriguez PC, Quiceno DG and Ochoa AC:
L-arginine availability regulates T-lymphocyte cell-cycle
progression. Blood. 109:1568–1573. 2007. View Article : Google Scholar
|
|
111
|
Zheng Y, Yao Y, Ge T, Ge S, Jia R, Song X
and Zhuang A: Amino acid metabolism reprogramming: Shedding new
light on T cell anti-tumor immunity. J Exp Clin Cancer Res.
42:2912023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Fujimura T, Mahnke K and Enk AH: Myeloid
derived suppressor cells and their role in tolerance induction in
cancer. J Dermatol Sci. 59:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Steggerda SM, Bennett MK, Chen J, Emberley
E, Huang T, Janes JR, Li W, MacKinnon AL, Makkouk A, Marguier G, et
al: Inhibition of arginase by CB-1158 blocks myeloid cell-mediated
immune suppression in the tumor microenvironment. J Immunother
Cancer. 5:1012017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Portale F and Di Mitri D: NK cells in
cancer: Mechanisms of dysfunction and therapeutic potential. Int J
Mol Sci. 24:95212023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Raber PL, Thevenot P, Sierra R,
Wyczechowska D, Halle D, Ramirez ME, Ochoa AC, Fletcher M, Velasco
C, Wilk A, et al: Subpopulations of myeloid-derived suppressor
cells impair T cell responses through independent nitric
oxide-related pathways. Int J Cancer. 134:2853–2864. 2014.
View Article : Google Scholar
|
|
116
|
Li W, Zhang X, Chen Y, Xie Y, Liu J, Feng
Q, Wang Y, Yuan W and Ma J: G-CSF is a key modulator of MDSC and
could be a potential therapeutic target in colitis-associated
colorectal cancers. Protein Cell. 7:130–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
OuYang LY, Wu XJ, Ye SB, Zhang RX, Li ZL,
Liao W, Pan ZZ, Zheng LM, Zhang XS, Wang Z, et al: Tumor-induced
myeloid-derived suppressor cells promote tumor progression through
oxidative metabolism in human colorectal cancer. J Transl Med.
13:472015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Corzo CA, Cotter MJ, Cheng P, Cheng F,
Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC and
Gabrilovich DI: Mechanism regulating reactive oxygen species in
tumor-induced myeloid-derived suppressor cells. J Immunol.
182:5693–5701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Nagaraj S, Gupta K, Pisarev V, Kinarsky L,
Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich DI: Altered
recognition of antigen is a mechanism of CD8+ T cell
tolerance in cancer. Nat Med. 13:828–835. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Jachetti E, Sangaletti S, Chiodoni C,
Ferrara R and Colombo MP: Modulation of PD-1/PD-L1 axis in
myeloid-derived suppressor cells by anti-cancer treatments. Cell
Immunol. 362:1043012021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhu J, Powis de Tenbossche CG, Cané S,
Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P,
Uyttenhove C and Van den Eynde BJ: Resistance to cancer
immunotherapy mediated by apoptosis of tumor-infiltrating
lymphocytes. Nat Commun. 8:14042017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Trovato R, Canè S, Petrova V, Sartoris S,
Ugel S and De Sanctis F: The engagement between MDSCs and
Metastases: Partners in crime. Front Oncol. 10:1652020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Lasser SA, Ozbay Kurt FG, Arkhypov I,
Utikal J and Umansky V: Myeloid-derived suppressor cells in cancer
and cancer therapy. Nat Rev Clin Oncol. 21:147–164. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lu C, Redd PS, Lee JR, Savage N and Liu K:
The expression profiles and regulation of PD-L1 in tumor-induced
myeloid-derived suppressor cells. Oncoimmunology. 5:e12471352016.
View Article : Google Scholar
|
|
127
|
Chiu DK, Tse AP, Xu IM, Di Cui J, Lai RK,
Li LL, Koh HY, Tsang FH, Wei LL, Wong CM, et al: Hypoxia inducible
factor HIF-1 promotes myeloid-derived suppressor cells accumulation
through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun.
8:5172017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zhou J, Qu Z, Sun F, Han L, Li L, Yan S,
Stabile LP, Chen LF, Siegfried JM and Xiao G: Myeloid STAT3
promotes lung tumorigenesis by transforming tumor
immunosurveillance into tumor-promoting inflammation. Cancer
Immunol Res. 5:257–268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Halaby MJ and McGaha TL: Amino acid
transport and metabolism in myeloid function. Front Immunol.
12:6952382021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Prendergast GC, Malachowski WJ, Mondal A,
Scherle P and Muller AJ: Indoleamine 2,3-dioxygenase and its
therapeutic inhibition in cancer. Int Rev Cell Mol Biol.
336:175–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Arshad J, Rao A, Repp ML, Rao R, Wu C and
Merchant JL: Myeloid-derived suppressor cells: Therapeutic target
for gastrointestinal cancers. Int J Mol Sci. 25:29852024.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Neurath MF, Weigmann B, Finotto S,
Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E,
Mudter J, Galle PR, et al: The transcription factor T-bet regulates
mucosal T cell activation in experimental colitis and Crohn's
disease. J Exp Med. 195:1129–1143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Lúdvíksson BR, Seegers D, Resnick AS and
Strober W: The effect of TGF-beta1 on immune responses of naïve
versus memory CD4+ Th1/Th2 T cells. Eur J Immunol. 30:2101–2111.
2000. View Article : Google Scholar
|
|
134
|
Singh S, Gouri V and Samant M: TGF-β in
correlation with tumor progression, immunosuppression and targeted
therapy in colorectal cancer. Med Oncol. 40:3352023. View Article : Google Scholar
|
|
135
|
Takaku S, Terabe M, Ambrosino E, Peng J,
Lonning S, McPherson JM and Berzofsky JA: Blockade of TGF-beta
enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J
Cancer. 126:1666–1674. 2010. View Article : Google Scholar
|
|
136
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE,
Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid
suppressor cells mediate the development of tumor-induced T
regulatory cells and T-cell anergy in tumor-bearing host. Cancer
Res. 66:1123–1131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Han J, Dong L, Wu M and Ma F: Dynamic
polarization of tumor-associated macrophages and their interaction
with intratumoral T cells in an inflamed tumor microenvironment:
From mechanistic insights to therapeutic opportunities. Front
Immunol. 14:11603402023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sinha P, Clements VK, Bunt SK, Albelda SM
and Ostrand-Rosenberg S: Cross-talk between myeloid-derived
suppressor cells and macrophages subverts tumor immunity toward a
type 2 response. J Immunol. 179:977–983. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Peng P, Lou Y, Wang S, Wang J, Zhang Z, Du
P, Zheng J, Liu P and Xu LX: Activated NK cells reprogram MDSCs via
NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after
cryo-thermal therapy. J Immunother Cancer. 10:e0057692022.
View Article : Google Scholar
|
|
140
|
Yue J, Li J, Ma J, Zhai Y, Shen L, Zhang
W, Li L and Fu R: Myeloid-derived suppressor cells inhibit natural
killer cells in myelodysplastic syndromes through the TIGIT/CD155
pathway. Hematology. 28:21663332023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Liu G, Bi Y, Shen B, Yang H, Zhang Y, Wang
X, Liu H, Lu Y, Liao J, Chen X and Chu Y: SIRT1 limits the function
and fate of myeloid-derived suppressor cells in tumors by
orchestrating HIF-1α-dependent glycolysis. Cancer Res. 74:727–737.
2014. View Article : Google Scholar
|
|
142
|
O'Donnell C, Mahmoud A, Keane J, Murphy C,
White D, Carey S, O'Riordain M, Bennett MW, Brint E and Houston A:
An antitumorigenic role for the IL-33 receptor, ST2L, in colon
cancer. Br J Cancer. 114:37–43. 2016. View Article : Google Scholar :
|
|
143
|
Wang D, Sun H, Wei J, Cen B and DuBois RN:
CXCL1 is critical for premetastatic niche formation and metastasis
in colorectal cancer. Cancer Res. 77:3655–3665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Gao Y, Bado I, Wang H, Zhang W, Rosen JM
and Zhang XHF: Metastasis organotropism: Redefining the congenial
soil. Dev Cell. 49:375–391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Li B, Zhang S, Huang N, Chen H, Wang P,
Yang J and Li Z: CCL9/CCR1 induces myeloid-derived suppressor cell
recruitment to the spleen in a murine H22 orthotopic hepatoma
model. Oncol Rep. 41:608–618. 2019.
|
|
146
|
Cui TX, Kryczek I, Zhao L, Zhao E, Kuick
R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, et al:
Myeloid-derived suppressor cells enhance stemness of cancer cells
by inducing microRNA101 and suppressing the corepressor CtBP2.
Immunity. 39:611–621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Di Mitri D, Toso A, Chen JJ, Sarti M,
Pinton S, Jost TR, D'Antuono R, Montani E, Garcia-Escudero R,
Guccini I, et al: Tumour-infiltrating Gr-1+ myeloid cells
antagonize senescence in cancer. Nature. 515:134–137. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Yan HH, Pickup M, Pang Y, Gorska AE, Li Z,
Chytil A, Geng Y, Gray JW, Moses HL and Yang L: Gr-1+CD11b+ myeloid
cells tip the balance of immune protection to tumor promotion in
the premetastatic lung. Cancer Res. 70:6139–6149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Long L, Xiong W, Lin F, Hou J, Chen G,
Peng T, He Y, Wang R, Xu Q and Huang Y: Regulating lactate-related
immunometabolism and EMT reversal for colorectal cancer liver
metastases using shikonin targeted delivery. J Exp Clin Cancer Res.
42:1172023. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Taki M, Abiko K, Ukita M, Murakami R,
Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N and Mandai
M: Tumor immune microenvironment during epithelial-mesenchymal
transition. Clin Cancer Res. 27:4669–4679. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wang Y, Jia A, Bi Y, Wang Y, Yang Q, Cao
Y, Li Y and Liu G: Targeting myeloid-derived suppressor cells in
cancer immunotherapy. Cancers (Basel). 12:26262020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Qu P, Wang LZ and Lin PC: Expansion and
functions of myeloid-derived suppressor cells in the tumor
microenvironment. Cancer Lett. 380:253–256. 2016. View Article : Google Scholar
|
|
153
|
De Cicco P, Ercolano G and Ianaro A: The
new era of cancer immunotherapy: Targeting myeloid-derived
suppressor cells to overcome immune evasion. Front Immunol.
11:16802020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Law AMK, Valdes-Mora F and Gallego-Ortega
D: Myeloid-derived suppressor cells as a therapeutic target for
cancer. Cells. 9:5612020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Li W, Wu K, Zhao E, Shi L, Li R, Zhang P,
Yin Y, Shuai X, Wang G and Tao K: HMGB1 recruits myeloid derived
suppressor cells to promote peritoneal dissemination of colon
cancer after resection. Biochem Biophys Res Commun. 436:156–161.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Eriksson E, Wenthe J, Irenaeus S, Loskog A
and Ullenhag G: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while
restoring the teff/treg ratio in patients with pancreatic cancer. J
Transl Med. 14:2822016. View Article : Google Scholar
|
|
157
|
John David K, Amy VP, Natasha MS, Asha NK
and Kebin L: 5-Fluorouracil regulation of myeloid-derived
suppressor cell differentiation in vitro and in vivo. J Immunol.
198(Suppl 1): S205.52017. View Article : Google Scholar
|
|
158
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Kanterman J, Sade-Feldman M, Biton M,
Ish-Shalom E, Lasry A, Goldshtein A, Hubert A and Baniyash M:
Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on
myeloid-derived suppressor cells and colorectal cancer outcomes.
Cancer Res. 74:6022–6035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Talmadge JE, Hood KC, Zobel LC, Shafer LR,
Coles M and Toth B: Chemoprevention by cyclooxygenase-2 inhibition
reduces immature myeloid suppressor cell expansion. Int
Immunopharmacol. 7:140–151. 2007. View Article : Google Scholar
|
|
161
|
Osada T, Chong G, Tansik R, Hong T,
Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, et al:
The effect of anti-VEGF therapy on immature myeloid cell and
dendritic cells in cancer patients. Cancer Immunol Immunother.
57:1115–1124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Dominguez GA, Condamine T, Mony S,
Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein
N, et al: selective targeting of myeloid-derived suppressor cells
in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody.
Clin Cancer Res. 23:2942–2950. 2017. View Article : Google Scholar :
|
|
163
|
Fultang L, Panetti S, Ng M, Collins P,
Graef S, Rizkalla N, Booth S, Lenton R, Noyvert B, Shannon-Lowe C,
et al: MDSC targeting with Gemtuzumab ozogamicin restores T cell
immunity and immunotherapy against cancers. EBioMedicine.
47:235–246. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
De Sanctis F, Solito S, Ugel S, Molon B,
Bronte V and Marigo I: MDSCs in cancer: Conceiving new prognostic
and therapeutic targets. Biochim Biophys Acta. 1865:35–48.
2016.
|
|
165
|
Hinshaw DC and Shevde LA: The tumor
microenvironment innately modulates cancer progression. Cancer Res.
79:4557–4566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhou J, Nefedova Y, Lei A and Gabrilovich
D: Neutrophils and PMN-MDSC: Their biological role and interaction
with stromal cells. Semin Immunol. 35:19–28. 2018. View Article : Google Scholar
|
|
167
|
Park SM and Youn JI: Role of
myeloid-derived suppressor cells in immune checkpoint inhibitor
therapy in cancer. Arch Pharm Res. 42:560–566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Cheng Y, Ma XL, Wei YQ and Wei XW:
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in
cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer.
1871:289–312. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Yan G, Zhao H, Zhang Q, Zhou Y, Wu L, Lei
J, Wang X, Zhang J, Zhang X, Zheng L, et al: A
RIPK3-PGE2 circuit mediates myeloid-derived suppressor
cell-potentiated colorectal carcinogenesis. Cancer Res.
78:5586–5599. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Umansky V, Blattner C, Gebhardt C and
Utikal J: CCR5 in recruitment and activation of myeloid-derived
suppressor cells in melanoma. Cancer Immunol Immunother.
66:1015–1023. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Tan MCB, Goedegebuure PS, Belt BA,
Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS and
Linehan DC: Disruption of CCR5-dependent homing of regulatory T
cells inhibits tumor growth in a murine model of pancreatic cancer.
J Immunol. 182:1746–1755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Zhang X, Haney KM, Richardson AC, Wilson
E, Gewirtz DA, Ware JL, Zehner ZE and Zhang Y: Anibamine, a natural
product CCR5 antagonist, as a novel lead for the development of
anti-prostate cancer agents. Bioorg Med Chem Lett. 20:4627–4630.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Velasco-Velázquez M, Jiao X, De La Fuente
M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist
blocks metastasis of basal breast cancer cells. Cancer Res.
72:3839–3850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Deming DA: Advances in immunotherapeutic
strategies for colorectal cancer commentary on: tumoral immune cell
exploitation in colorectal cancer metastases can be targeted
effectively by anti-CCR5 therapy in cancer patients by Halama et
al. J Immunother Cancer. 4:932016. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Cannarile MA, Weisser M, Jacob W, Jegg AM,
Ries CH and Rüttinger D: Colony-stimulating factor 1 receptor
(CSF1R) inhibitors in cancer therapy. J Immunother Cancer.
5:532017. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Holmgaard RB, Zamarin D, Lesokhin A,
Merghoub T and Wolchok JD: Targeting myeloid-derived suppressor
cells with colony stimulating factor-1 receptor blockade can
reverse immune resistance to immunotherapy in indoleamine
2,3-dioxygenase-expressing tumors. EBioMedicine. 6:50–58. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Mitchem JB, Brennan DJ, Knolhoff BL, Belt
BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L,
Piwnica-Worms D, et al: Targeting tumor-infiltrating macrophages
decreases tumor-initiating cells, relieves immunosuppression, and
improves chemotherapeutic responses. Cancer Res. 73:1128–1141.
2013. View Article : Google Scholar
|
|
178
|
Lonardi S, Licini S, Micheletti A, Finotti
G, Vermi W and Cassatella MA: Potential contribution of
tumor-associated slan+ cells as anti-CSF-1R targets in
human carcinoma. J Leukoc Biol. 103:559–564. 2018. View Article : Google Scholar
|
|
179
|
Lin S, Wang J, Wang L, Wen J, Guo Y, Qiao
W, Zhou J, Xu G and Zhi F: Phosphodiesterase-5 inhibition
suppresses colonic inflammation-induced tumorigenesis via blocking
the recruitment of MDSC. Am J Cancer Res. 7:41–52. 2017.PubMed/NCBI
|
|
180
|
Liang H, Deng L, Hou Y, Meng X, Huang X,
Rao E, Zheng W, Mauceri H, Mack M, Xu M, et al: Host
STING-dependent MDSC mobilization drives extrinsic radiation
resistance. Nat Commun. 8:17362017. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
De Santo C, Serafini P, Marigo I, Dolcetti
L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi
M, et al: Nitroaspirin corrects immune dysfunction in tumor-bearing
hosts and promotes tumor eradication by cancer vaccination. Proc
Natl Acad Sci USA. 102:4185–4190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Molon B, Viola A and Bronte V: Smoothing T
cell roads to the tumor: Chemokine post-translational regulation.
Oncoimmunology. 1:390–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Chen HM, Ma G, Gildener-Leapman N,
Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M,
Sung M, et al: Myeloid-derived suppressor cells as an immune
parameter in patients with concurrent sunitinib and stereotactic
body radiotherapy. Clin Cancer Res. 21:4073–4085. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Nagaraj S, Youn JI, Weber H, Iclozan C, Lu
L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, et al:
Anti-inflammatory triterpenoid blocks immune suppressive function
of MDSCs and improves immune response in cancer. Clin Cancer Res.
16:1812–1823. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Chalmin F, Ladoire S, Mignot G, Vincent J,
Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau
D, et al: Membrane-associated Hsp72 from tumor-derived exosomes
mediates STAT3-dependent immunosuppressive function of mouse and
human myeloid-derived suppressor cells. J Clin Invest. 120:457–471.
2010.PubMed/NCBI
|
|
186
|
Bertocchi A, Carloni S, Ravenda PS,
Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D,
Asnicar F, et al: Gut vascular barrier impairment leads to
intestinal bacteria dissemination and colorectal cancer metastasis
to liver. Cancer Cell. 39:708–724.e11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Mei Y, Zhu Y, Yong KSM, Hanafi ZB, Gong H,
Liu Y, Teo HY, Hussain M, Song Y, Chen Q and Liu H: IL-37 dampens
immunosuppressive functions of MDSCs via metabolic reprogramming in
the tumor microenvironment. Cell Rep. 43:1138352024. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Hengesbach LM and Hoag KA: Physiological
concentrations of retinoic acid favor myeloid dendritic cell
development over granulocyte development in cultures of bone marrow
cells from mice. J Nutr. 134:2653–2659. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Nefedova Y, Fishman M, Sherman S, Wang X,
Beg AA and Gabrilovich DI: Mechanism of all-trans retinoic acid
effect on tumor-associated myeloid-derived suppressor cells. Cancer
Res. 67:11021–11028. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Mirza N, Fishman M, Fricke I, Dunn M,
Neuger AM, Frost TJ, Lush RM, Antonia S and Gabrilovich DI:
All-trans-retinoic acid improves differentiation of myeloid cells
and immune response in cancer patients. Cancer Res. 66:9299–9307.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G,
Liu A, Wang TC and Yang CS: Curcumin induces the differentiation of
myeloid-derived suppressor cells and inhibits their interaction
with cancer cells and related tumor growth. Cancer Prev Res
(Phila). 5:205–215. 2012. View Article : Google Scholar
|
|
192
|
Carroll RE, Benya RV, Turgeon DK, Vareed
S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C,
Meyskens FL Jr and Brenner DE: Phase IIa clinical trial of curcumin
for the prevention of colorectal neoplasia. Cancer Prev Res
(Phila). 4:354–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Daurkin I, Eruslanov E, Vieweg J and
Kusmartsev S: Generation of antigen-presenting cells from
tumor-infiltrated CD11b myeloid cells with DNA demethylating agent
5-aza-2′-deoxycytidine. Cancer Immunol Immunother. 59:697–706.
2010. View Article : Google Scholar
|
|
194
|
Zoglmeier C, Bauer H, Noerenberg D,
Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S and
Bourquin C: CpG blocks immunosuppression by myeloid-derived
suppressor cells in tumor-bearing mice. Clin Cancer Res.
17:1765–1775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Meyer C, Cagnon L, Costa-Nunes CM,
Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E and
Speiser DE: Frequencies of circulating MDSC correlate with clinical
outcome of melanoma patients treated with ipilimumab. Cancer
Immunol Immunother. 63:247–257. 2014. View Article : Google Scholar
|
|
196
|
Di Giacomo AM, Schenker M, Medioni J,
Mandziuk S, Majem M, Gravis G, Cornfeld M, Ranganathan S, Lou S and
Csoszi T: A phase II study of retifanlimab, a humanized anti-PD-1
monoclonal antibody, in patients with solid tumors (POD1UM-203).
ESMO Open. 9:1023872024. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Kim W, Chu TH, Nienhüser H, Jiang Z, Del
Portillo A, Remotti HE, White RA, Hayakawa Y, Tomita H, Fox JG, et
al: PD-1 signaling promotes tumor-infiltrating myeloid-derived
suppressor cells and gastric tumorigenesis in mice.
Gastroenterology. 160:781–796. 2021. View Article : Google Scholar
|
|
198
|
Kalyan A, Kircher S, Shah H, Mulcahy M and
Benson A: Updates on immunotherapy for colorectal cancer. J
Gastrointest Oncol. 9:160–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Wang C, Zheng X, Zhang J, Jiang X, Wang J,
Li Y, Li X, Shen G, Peng J, Zheng P, et al: CD300ld on neutrophils
is required for tumour-driven immune suppression. Nature.
621:830–839. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Kumar V, Cheng P, Condamine T, Mony S,
Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G,
Penman E, et al: CD45 phosphatase inhibits STAT3 transcription
factor activity in myeloid cells and promotes tumor-associated
macrophage differentiation. Immunity. 44:303–315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Su MT, Kumata S, Endo S, Okada Y and Takai
T: LILRB4 promotes tumor metastasis by regulating MDSCs and
inhibiting miR-1 family miRNAs. Oncoimmunology. 11:20609072022.
View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Ostrand-Rosenberg S, Beury DW, Parker KH
and Horn LA: Survival of the fittest: How myeloid-derived
suppressor cells survive in the inhospitable tumor
microenvironment. Cancer Immunol Immunother. 69:215–221. 2020.
View Article : Google Scholar :
|
|
203
|
Beury DW, Carter KA, Nelson C, Sinha P,
Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N and
Ostrand-Rosenberg S: Myeloid-derived suppressor cell survival and
function are regulated by the transcription factor Nrf2. J Immunol.
196:3470–3478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Condamine T, Kumar V, Ramachandran IR,
Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide
RH, English NR, et al: ER stress regulates myeloid-derived
suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin
Invest. 124:2626–2639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Wang Y, Zheng L, Shang W, Yang Z, Li T,
Liu F, Shao W, Lv L, Chai L, Qu L, et al: Wnt/beta-catenin
signaling confers ferroptosis resistance by targeting GPX4 in
gastric cancer. Cell Death Differ. 29:2190–2202. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Conche C, Finkelmeier F, Pešić M, Nicolas
AM, Böttger TW, Kennel KB, Denk D, Ceteci F, Mohs K, Engel E, et
al: Combining ferroptosis induction with MDSC blockade renders
primary tumours and metastases in liver sensitive to immune
checkpoint blockade. Gut. 72:1774–1782. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Bebelman MP, Smit MJ, Pegtel DM and Baglio
SR: Biogenesis and function of extracellular vesicles in cancer.
Pharmacol Ther. 188:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS,
Yan YR, Song FY, Wang FF, Zhu XH, Liao WJ, et al: CAFs secreted
exosomes promote metastasis and chemotherapy resistance by
enhancing cell stemness and epithelial-mesenchymal transition in
colorectal cancer. Mol Cancer. 18:912019. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Xu Z, Zeng S, Gong Z and Yan Y:
Exosome-based immunotherapy: A promising approach for cancer
treatment. Mol Cancer. 19:1602020. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Wang Y, Yin K, Tian J, Xia X, Ma J, Tang
X, Xu H and Wang S: Granulocytic myeloid-derived suppressor cells
promote the stemness of colorectal cancer cells through exosomal
S100A9. Adv Sci (Weinh). 6:19012782019. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Wang Y, Liu H, Zhang Z, Bian D, Shao K,
Wang S and Ding Y: G-MDSC-derived exosomes mediate the
differentiation of M-MDSC into M2 macrophages promoting
colitis-to-cancer transition. J Immunother Cancer. 11:e0061662023.
View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang
G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on
cancer biology and clinical applications. Mol Cancer. 17:1472018.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Matsumura T, Sugimachi K, Iinuma H,
Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano
Y, et al: Exosomal microRNA in serum is a novel biomarker of
recurrence in human colorectal cancer. Br J Cancer. 113:275–281.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Huang D, Sun W, Zhou Y, Li P, Chen F, Chen
H, Xia D, Xu E, Lai M, Wu Y and Zhang H: Mutations of key driver
genes in colorectal cancer progression and metastasis. Cancer
Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Jayaraman P, Parikh F, Newton JM, Hanoteau
A, Rivas C, Krupar R, Rajapakshe K, Pathak R, Kanthaswamy K,
MacLaren C, et al: TGF-β1 programmed myeloid-derived suppressor
cells (MDSC) acquire immune-stimulating and tumor killing activity
capable of rejecting established tumors in combination with
radiotherapy. Oncoimmunology. 7:e14908532018. View Article : Google Scholar
|
|
217
|
Li X, Wen D, Li X, Yao C, Chong W and Chen
H: Identification of an immune signature predicting prognosis risk
and lymphocyte infiltration in colon cancer. Front Immunol.
11:16782020. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Javle MM, Bridgewater JA, Gbolahan OB,
Jungels C, Cho MT, Papadopoulos KP, Thistlethwaite FC, Canon JLR,
Cheng L, Ioannidis S, et al: A phase I/II study of safety and
efficacy of the arginase inhibitor INCB001158 plus chemotherapy in
patients (Pts) with advanced biliary tract cancers. J Clin Oncol.
39(Suppl 3): S3112021. View Article : Google Scholar
|
|
219
|
Lorentzen CL, Martinenaite E, Kjeldsen JW,
Holmstroem RB, Mørk SK, Pedersen AW, Ehrnrooth E, Andersen MH and
Svane IM: Arginase-1 targeting peptide vaccine in patients with
metastatic solid tumors-A phase I trial. Front Immunol.
13:10230232022. View Article : Google Scholar
|
|
220
|
Zeng Z, Lan T, Wei Y and Wei X: CCL5/CCR5
axis in human diseases and related treatments. Genes Dis. 9:12–27.
2022. View Article : Google Scholar
|
|
221
|
Snajdauf M, Havlova K, Vachtenheim J Jr,
Ozaniak A, Lischke R, Bartunkova J, Smrz D and Strizova Z: The
TRAIL in the treatment of human cancer: An update on clinical
trials. Front Mol Biosci. 8:6283322021. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Isambert N, Hervieu A, Rébé C, Hennequin
A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne
E, et al: Fluorouracil and bevacizumab plus anakinra for patients
with metastatic colorectal cancer refractory to standard therapies
(IRAFU): A single-arm phase 2 study. Oncoimmunology.
7:e14743192018. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Schmitz-Winnenthal FH, Hohmann N, Schmidt
T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S,
Breiner KM, Mikus G, et al: A phase 1 trial extension to assess
immunologic efficacy and safety of prime-boost vaccination with
VXM01, an oral T cell vaccine against VEGFR2, in patients with
advanced pancreatic cancer. Oncoimmunology. 7:e13035842018.
View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Johnson B, Kopetz S, Hwang H, Yuan Y,
DePinho RA, Zebala J and Overman MJ: STOPTRAFFIC-1: A phase I/II
trial of SX-682 in combination with nivolumab for refractory
RAS-mutated microsatellite stable (MSS) metastatic colorectal
cancer (mCRC). J Clin Oncol. 40(Suppl 16): TPS36382022. View Article : Google Scholar
|
|
225
|
Hanna CR, O'Cathail SM, Graham J, Adams R
and Roxburgh CSD: Immune checkpoint inhibition as a strategy in the
neoadjuvant treatment of locally advanced rectal cancer. J
Immunother Precis Oncol. 4:86–104. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Lizardo DY, Kuang C, Hao S, Yu J, Huang Y
and Zhang L: Immunotherapy efficacy on mismatch repair-deficient
colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev
Cancer. 1874:1884472020. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Hull MA, Ow PL, Ruddock S, Brend T, Smith
AF, Marshall H, Song M, Chan AT, Garrett WS, Yilmaz O, et al:
Randomised, placebo-controlled, phase 3 trial of the effect of the
omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on
colorectal cancer recurrence and survival after surgery for
resectable liver metastases: EPA for metastasis trial 2 (EMT2)
study protocol. BMJ Open. 13:e0774272023. View Article : Google Scholar
|
